PAREXEL Expands Regional Distribution Center and Supply Depot Network to Enhance Global Clinical Logistics Services
PAREXEL International Corporation, a leading global biopharmaceutical services provider, has announced the expansion of its global Clinical Logistics Services (CLS) capabilities. A new, state-of-the-art distribution center in Singapore and the recent expansion of the Company’s facilities in Billerica, Mass., will help PAREXEL more effectively manage clients’ global clinical trial supply requirements.
PAREXEL’s Clinical Logistics Services provides synchronized coordination of clinical trial supplies, central lab services, and ancillary supplies worldwide to ensure safe and timely distribution. The Company offers risk evaluation and mitigation planning for in-time-investigational-site supply, as well as expertise in global import/export compliance. New capabilities include secondary packaging and labeling services. The facility expansion builds upon PAREXEL’s considerable global clinical logistics infrastructure in North America, Latin America, Europe, Africa and the Asia/Pacific region.
“As clinical trials increase in size and complexity, clients are challenged to develop and implement strategies that create consistent sourcing, manufacturing, storage and distribution processes along the supply chain,” said Mark A. Goldberg, President and Chief Operating Officer, PAREXEL. “Our investments in these important distribution centers and depots are part of the company’s ongoing efforts to simplify the clinical trial journey for biopharmaceutical clients by supporting their growing global supply and logistics needs.”
PAREXEL’s clinical logistics facilities offer sophisticated capabilities that include enhanced expiry and update labeling services. These services eliminate the need to return supplies to the manufacturing organization, reduce study start-up time and help ensure timely first-patient-in milestones. Additional capabilities include a distribution and warehousing infrastructure to manage and transport clinical trial supplies to locations worldwide, as well as leading technology systems that track and trace shipments and manage inventory levels.
“PAREXEL continues to build a global network of storage and distribution facilities with harmonized configurations that provide a consistent and reliable flow of materials needed in the clinical trial process,” said Kurt Norris, Corporate Vice President, Clinical Logistics Services, PAREXEL. “This reflects our commitment to provide leading-edge management of clinical trial materials to clients across the globe.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.